InnovAge PACE Sponsors Documentary Spotlighting National Crisis in Family Caregiving
'At InnovAge, our mission is rooted in supporting seniors and those who care for them,' says InnovAge CEO Patrick Blair. ' Caregiving demonstrates the critical role caregivers play across the country. We are proud to help bring these powerful stories to light as we work every day to deliver dignified, coordinated care to older adults through our PACE model.'
InnovAge's sponsorship supports PBS in raising national awareness about the caregiving crisis— highlighted in the documentary through stories of families managing funding cuts, policy shifts, and workforce challenges.
'Documentaries like Caregiving remind us that caregiving is everyone's story,' Blair continued. 'Through PACE, our participants can stay safely at home with dignity and autonomy while enabling their loved ones to enjoy that time with them, while also easing the stress and pressure associated with senior care.'
About InnovAge
InnovAge is a market leader in managing the care of high-cost, frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge's person-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — 'win.' As of March 31, 2025, InnovAge served approximately 7,530 participants across 20 centers in six states. https://www.innovage.com
Lara Hazenfield
Manager, Public Relations & Content Creation | InnovAge
720-884-7568 cell | [email protected] | www.InnovAge.com
John Eddy
Goldin Solutions for InnovAge
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
Which states' air quality are most impacted by Canadian wildfires? See map.
As wildfires spread across Canada, air quality in the U.S. continues to be impacted, and people sensitive to air pollution could face "serious health effects," according to a government website that tracks air quality in the United States. There are 59 uncontrolled wildfires and 108 controlled wildfires across Canada as of Wednesday, July 30, the country's National Wildland Fire Situation Report said on its website. To date this year, there have been 3,582 fires. Fires have burned nearly 1.5 million acres since the start of 2025, according to the country's report. The smoke floating over the border shared between America and Canada is now impacting air quality in states as far south as Texas, AirNow's data shows. The EPA has declared the air quality in states near the Canadian border as "unhealthy or "unhealthy for sensitive groups." See maps and impacted states. See map of Canadian wildfires See map of US wildfires and smoke Which states are most affected by the Canadian fires? As of 9 a.m. ET on Tuesday, Aug. 5, areas in the following states are "Unhealthy for sensitive groups," according to AirNow: People with pre-existing medical conditions, like asthma, will be more sensitive to conditions that are deemed "Unhealthy for Sensitive Groups." "Members of sensitive groups may experience health effects," according to AirNow. 'Unhealthy' air quality States' air quality is measured by the EPA's U.S. Air Quality Index, according to AirNow's website. Values with an index of 151 to 200 are deemed unhealthy for all. As of 9 a.m. ET on Tuesday, Aug. 5, areas in the following states have been deemed unhealthy, according to AirNow's air quality map: "Some members of the general public may experience health effects," AirNow states on its website. However, "members of sensitive groups may experience more serious health effects." To learn if your area's air quality is affected by the wildfires, visit AirNow's interactive map. Side effects of inhaling wildfire smoke Wildfire smoke can irritate one's eyes, nose, and throat and cause the following symptoms: Particulate matter (PM) is one of the main components of wildfire smoke, comprised of small particles of solids or liquids suspended in the air, USA TODAY previously reported. According to Yale Medicine, the particles can be 10 micrometers, PM 10, or as small as 2.5 micrometers, PM 2.5, and the smaller one poses a lot of health risks. PM 2.5 is so tiny that it can easily pass people's usual defense mechanisms and go deep into their lungs. Not only can it damage lung function, but it can also pass into the bloodstream and travel to other organs. The following is linked to exposure to the PM 2.5: Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram, and TikTok: @juliamariegz, or email her at jgomez@
Yahoo
an hour ago
- Yahoo
Pharmacovigilance Automation Market Size, Key Players and Trends 2025
The pharmacovigilance automation market is gaining strong momentum worldwide, with projections indicating it will generate hundreds of millions in revenue between 2025 and 2034. Ottawa, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The pharmacovigilance automation market size growth is being driven by rising investments, ongoing innovation, and increasing demand across the healthcare and pharmaceutical sectors, a study published by Towards Healthcare a sister firm of Precedence Research. Get a free sample to explore key trends, market drivers, and growth insights: A key reason for this expansion is the tightening of global drug safety regulations and the need to better manage the growing number of adverse drug reactions. To meet these challenges, companies are turning to advanced technologies like artificial intelligence, natural language processing (NLP), and machine learning. These tools are helping automate tasks such as collecting, identifying, and analyzing adverse events making the process faster, more accurate, and cost-effective. Regionally, North America is leading the market thanks to heavy R&D spending by pharma companies and a strong digital healthcare infrastructure. Meanwhile, Asia Pacific is emerging as the fastest-growing region, driven by a high volume of clinical trials and a robust regulatory landscape. Key Takeaways North America is dominant in the pharmacovigilance automation market in 2024 with a 45% share. Asia Pacific is estimated to grow at the fastest CAGR from 2025 to 2035. By function, the case processing & reporting segment for the largest market revenue in 2024, with a 42% share. By function, the regulatory compliance automation segment is estimated to fastest-growing over the forecast period, 2025 to 2035. By technology, the robotic process automation (RPA) segment is dominant in the market in 2024 with a 36% share. By technology, the natural language processing (NLP) segment is expected to register the fastest growth over the forecast period, 2025 to 2035. By deployment mode, the cloud-based segment is dominant in the pharmacovigilance automation market in 2024, and it is expected to sustain the position during the forecast period with a 61% share. By end user, the pharmaceutical & biotechnology companies segment is dominant in the market in 2024 with a 48% share. By end user, the academic & research institutions segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Market Overview & Potential What is the Growth Potential Responsible for the Growth of the Pharmacovigilance Automation Market? The growth of the market is driven by the growing demand and increasing drug development, fueled by the expanding pharmaceutical industry's demand for safety monitoring systems, which in turn fuels the growth of the market. The rising adverse drug reactions monitoring due to increasing chronic diseases demands effective pharmacovigilance practices. Other key growth drivers are the regulatory stringency, technological advancement to automate the task and improve the accuracy, and to streamline the assessment boosts the growth and expansion of the market. What are the Growing Trends Associated with the Pharmacovigilance Automation Market? AI and Machine Learning: AI and ML are increasingly utilized to automate various tasks such as identifying adverse events, extracting data from unstructured sources like social media, and monitoring literature. Automated Case Processing: Organizations are swiftly implementing automation for case handling, including intake, triage, and analysis, resulting in quicker reporting and greater efficiency. Big Data Analytics: Pharmacovigilance is employing big data analytics to detect patterns and correlations within large datasets, supporting signal detection and risk management. Real-World Evidence (RWE): The use of real-world data information collected outside clinical trials is on the rise, with automation playing a vital role in managing and analyzing this data effectively. Remote Work and Collaboration: The pandemic has sped up remote work adoption, and automation tools are facilitating improved collaboration and communication among pharmacovigilance teams. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growing Challenge in the Pharmacovigilance Automation Market? The key challenge that limits the growth of the Asia Pacific bioplastics market is the lack of sufficient funding for pharmacovigilance activities, resulting in limited implementation of advanced automation solutions, which limits the growth of the market. Other key challenge the is the shortage of skilled professionals who are experts in pharmacovigilance and automation technologies, which is a challenge and hinders the growth and expansion of the market. Regional Analysis How did North America Dominate the Pharmacovigilance Automation Market in 2024? North America dominated the pharmacovigilance automation market share by 45% in 2024, with a 45% share, driven by early adoption of automation in healthcare, including PV, which effectively manages inventory, orders, and tracking, ensuring proper medicine delivery and reducing errors. The FDA's Adverse Event Reporting System (FAERS) supports market growth by tracking adverse drug reactions and medication errors. Advanced technology infrastructure, stringent FDA regulations, and growing AI adoption promote pharmacovigilance automation. Emphasis on real-time data analytics, electronic health records integration, and robust drug safety frameworks drives automated adverse event reporting and signal detection to enhance patient safety and regulatory compliance. Canada's focus on digital health transformation, Health Canada's regulatory support, and investment in AI-powered pharmacovigilance tools promote automation. Collaboration among healthcare providers, researchers, and tech companies accelerates real-world data utilization, improving adverse event monitoring and drug safety through streamlined, automated reporting systems. What Made Asia Pacific Significantly Grow in the Pharmacovigilance Automation Market in 2024? The Asia Pacific region is projected to experience the fastest growth during the forecast period. Its rise is fueled by rapid product launches in healthcare, increasing consumer expectations, and the expanding use of digital health technology. Ongoing healthcare transformation, supported by policies, infrastructure development, and public-private partnerships, positions APAC to become a global leader in digital health, thus propelling market growth of market growth. China's expanding pharmaceutical industry, government initiatives for digital health, and adoption of big data and AI technologies drive pharmacovigilance automation. The National Medical Products Administration encourages automation to enhance drug safety surveillance, leveraging vast healthcare data to improve adverse event detection and regulatory oversight. India's growing pharmaceutical sector, government policies supporting digital health, and increased AI integration promote pharmacovigilance automation. The Central Drugs Standard Control Organization encourages automated adverse event reporting to enhance patient safety. Collaborative efforts between government, industry, and academia drive the adoption of technology for efficient drug safety monitoring. Get the latest insights on life science industry segmentation with our Annual Membership: Segmental Insights By function The case processing & reporting segment for the largest pharmacovigilance automation market revenue in 2024, with a 42% share. It provides data for investigating adverse effects, enabling the identification of new safety concerns and occasional assessment of the profit-to-challenge ratio for pharmaceutical use. It facilitates data exchange among stakeholders like patients, healthcare professionals, and authorities by sharing large volumes of safety information. Case reports play a key role in detecting new safety signals through the description of rare or delayed adverse effects that might not be observed in clinical trials. The regulatory compliance automation segment is estimated to fastest-growing over the forecast period, 2025 to 2035. Automation in regulatory compliance ensures that medications and healthcare devices meet strict standards of quality, safety, and efficacy before market release. Agencies such as the FDA, EMA, and WHO enforce guidelines like GMP, GCP, and GDP throughout all stages of development and distribution. Following these guidelines is crucial for maintaining public trust and ensuring success in the medical industry. By technology The robotic process automation (RPA) segment is dominant in the pharmacovigilance automation market in 2024 with a 36% share. Robotic process automation (RPA) enhances operational efficiency by streamlining workflows, reducing risks, and minimizing delays and rework, which lowers operational costs. RPA offers privacy and security benefits, helps pharmaceutical companies reduce human errors, and improves data accuracy to support better decision-making. In pharmacovigilance, RPA is especially valuable for faster adverse effect response times. The natural language processing (NLP) segment is expected to register the fastest growth over the forecast period, 2025 to 2035. NLP has become essential in pharmacovigilance, a field focused on monitoring and preventing drug-related adverse effects. It efficiently manages vast amounts of unstructured data such as patient records and social media posts, which provide real-world insights into drug effects. NLP aids in regulatory compliance and accelerates reporting to health authorities. By deployment mode The cloud-based segment is dominant in the pharmacovigilance automation market in 2024, and it is expected to sustain the position during the forecast period with a 61% share. Cloud solutions deliver robust security features like data encryption, secure access protocols, and regular backups. As an emerging tool, cloud-based systems in pharmacovigilance support seamless data integration by providing internet-based storage, computing services, analytics, and software, thus enhancing efficiency. By end user, The pharmaceutical & biotechnology companies segment is dominant in the pharmacovigilance automation market in 2024 with a 48% share. Pharmacovigilance companies share core goals with government agencies: protecting patients from harm by detecting hidden drug complexities early, identifying risk factors, debunking false safety signals, and addressing benefit challenges. PV raises awareness among healthcare professionals and patients regarding contraindications, indications, doses, administration routes, and adverse effects. The academic & research institutions segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Pharmacovigilance also hosts leading research platforms that improve patient care through informed prescribing and ensure government compliance. These collaborations with top industry players further fuel market growth. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: Recent Developments in the Pharmacovigilance Automation Market In July 2025, Tata Consultancy Services (TCS) was recognized as a Leader in Everest Group's PEAK Matrix for Pharmacovigilance (PV) Operations services. The report emphasizes TCS's extensive pharmacovigilance offerings, including device complaint management, medical device product quality issues, medical device reporting, and post-market surveillance as key strengths. TCS's flagship ADD safety platform is notably highlighted for its touchless processing of individual case safety reports (ICSRs), featuring integrated quality control, smart signal detection, literature surveillance, and safety report generation. In September 2024, Truliant Consulting releases a white paper titled AI and Automation in Pharmacovigilance: Transformative Trends and Future Outlook. This paper results from an open survey aimed at pharmaceutical companies to explore their adoption of artificial intelligence (AI) within their Pharmacovigilance (PV) frameworks. Top Companies and Their Contributions to the Market Company Contributions & Offerings Oracle Corporation Provides cloud-based safety and pharmacovigilance solutions, integrating AI for automated case processing and compliance management. Veeva Systems Inc. Offers cloud software tailored for life sciences, including pharmacovigilance modules that streamline safety data management and reporting. ArisGlobal Develops end-to-end drug safety and pharmacovigilance platforms with automation, AI, and regulatory compliance features. IQVIA Combines real-world data analytics with automation to enhance signal detection, adverse event reporting, and clinical safety workflows. Cognizant Technology Solutions Delivers IT and BPO services focusing on automated pharmacovigilance processes, leveraging AI and machine learning for data accuracy. Accenture Provides digital transformation and AI-driven pharmacovigilance automation services to optimize safety data workflows globally. Genpact Specializes in AI-powered pharmacovigilance automation, improving adverse event case processing and regulatory reporting efficiency. Tata Consultancy Services (TCS) Offers integrated technology solutions automating safety data capture, analysis, and regulatory submissions in pharmacovigilance. Parexel International Corporation Provides clinical research and safety automation services, enhancing pharmacovigilance with AI-enabled case management and reporting tools. ICON plc Focuses on clinical research and drug safety automation, utilizing advanced analytics and automated adverse event monitoring systems. Pharmacovigilance Automation Market Key Players List Oracle Corporation Veeva Systems Inc. ArisGlobal IQVIA Cognizant Technology Solutions Accenture Genpact Tata Consultancy Services (TCS) Parexel International Corporation ICON plc Capgemini SE PharmaLex GmbH Indegene Pvt Ltd BioClinica (part of ERT) Infosys Limited HCL Technologies Ennov Tech Mahindra Zifo RnD Solutions NNIT A/S Browse More Insights of Towards Healthcare: Global Pharmaceutical & Compounding Market Outlook (2024–2034) The pharmaceutical and healthcare packaging sectors are undergoing notable transformation, supported by rising demand for personalized treatments, automation, and regulatory compliance. Here's a breakdown of key market trajectories: GCC Compounding Pharmacy MarketThe GCC compounding pharmacy market is witnessing a strong upward trend. Valued at USD 16.39 million in 2024, it is expected to reach approximately USD 40.26 million by 2034, growing at a CAGR of 9.27%. This growth is driven by the increasing need for tailored medications across the Gulf region. Global Non-Sterile Compounding Pharmacy MarketThe non-sterile compounding pharmacy market was estimated at USD 5.97 billion in 2024 and is set to almost double by 2034, reaching around USD 12.11 billion. With a CAGR of 7.34%, the market reflects expanding demand for dosage flexibility and patient-specific drug formulations. Global Pharmacy Automation MarketThe pharmacy automation market is advancing rapidly as healthcare systems adopt technologies to streamline dispensing and improve safety. Starting at USD 6.35 billion in 2024, the market is projected to reach USD 16.65 billion by 2034, growing at a CAGR of 10.12%. Global Compounding Pharmacy MarketThe global compounding pharmacy market stood at USD 13.19 billion in 2023 and is projected to climb to USD 22.91 billion by 2034. This steady growth, at a CAGR of 5.15%, is propelled by rising chronic disease prevalence and the need for customized drug therapies. Global Vials Used in Compounding Pharmacy MarketThe vials used in compounding pharmacy market is set for strong revenue growth over the forecast period. The market is expanding in response to higher demand for safe and precise medication containers, especially in sterile compounding. Global Biotechnology & Pharmaceutical Services MarketThe biotechnology and pharmaceutical services market is projected to grow from USD 76.51 billion in 2024 to around USD 130.56 billion by 2034, at a CAGR of 5.48%. The market benefits from increased outsourcing, R&D intensity, and regulatory support. Global Biopharmaceuticals CRO MarketThe biopharmaceuticals CRO (Contract Research Organization) market is on a robust growth path. With rising R&D and a push for cost efficiency, the market is expected to generate significant revenue gains through 2034. Global Pharmaceutical Spray Drying MarketThe pharmaceutical spray drying market is valued at USD 2.37 billion in 2024 and forecast to nearly double, reaching USD 4.93 billion by 2034. A CAGR of 7.67% reflects the increased use of this technology for enhancing bioavailability in drug formulations. Global Ready-to-Use Pharmaceutical Packaging MarketThe ready-to-use pharmaceutical packaging market was valued at USD 10.4 billion in 2024 and is anticipated to reach USD 20.97 billion by 2034. Growing at a CAGR of 7.24%, this market is shaped by demand for efficiency, sterility, and compliance. Global Pharmaceutical Secondary Packaging MarketThe pharmaceutical secondary packaging market is estimated at USD 43.11 billion in 2024 and is expected to grow to USD 69.45 billion by 2034. With a CAGR of 4.94%, this segment is critical for safety labeling, tracking, and brand protection. Segments Covered in The Report By Function Case Processing & Reporting Case Intake Medical Review Data Entry & Coding Signal Detection & Management Literature Screening Regulatory Compliance Automation Risk Management & Benefit-Risk Evaluation Report Submission & Distribution Quality Control & Reconciliation By Technology Robotic Process Automation (RPA) Artificial Intelligence (AI) & Machine Learning Natural Language Processing (NLP) Cloud-Based PV Platforms Rules-Based Automation Tools Intelligent Automation By Deployment Mode On-Premises Cloud-Based By End User Pharmaceutical & Biotechnology Companies Contract Research Organizations (CROs) Pharmacovigilance Service Providers Regulatory Agencies Academic & Research Institutions By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait To invest in our premium strategic solution and customized market report options, click here: You can place an order or ask any questions, please feel free to contact us at sales@ Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 hours ago
- Business Upturn
D-dimer Testing Market Size to Hit USD 2.74 Billion by 2032, Fueled by Rising Incidence of Thrombotic Disorders and Aging Population
Austin, Aug. 05, 2025 (GLOBE NEWSWIRE) — D-dimer Testing Market Size & Growth Analysis: According to SNS Insider, The D-dimer Testing Market was valued at USD 1.83 billion in 2023 and is projected to reach USD 2.74 billion by 2032, growing at a CAGR of 4.59% during the forecast period 2024–2032. The U.S. D-dimer Testing Market alone contributed USD 0.43 billion in 2023 and is projected to reach USD 0.59 billion by 2032, showcasing consistent demand in a region with a high prevalence of thrombotic and cardiovascular diseases. Get Free Sample Report of the D-dimer Testing Market: D-dimer testing is increasingly being adopted for its critical role in diagnosing deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC). The rise in chronic conditions, aging global populations, and post-COVID-19 complications are expected to further fuel demand. Key Growth Drivers: Rising Prevalence of Thrombotic Events: Sedentary lifestyles, obesity, and smoking contribute to growing cases of DVT and PE. Aging Population: Older adults are more susceptible to clotting disorders, increasing demand for rapid diagnostic solutions. Point-of-Care Testing (POCT) Advances: Technological innovations are expanding test accessibility across outpatient and emergency care settings. Healthcare Infrastructure Expansion in Emerging Markets: Developing regions are investing in diagnostic technologies to improve patient outcomes. Major Players Analysis Listed in this Report are: Siemens Healthcare Biomedica Diagnostics Abbott Thermo Fisher Scientific Inc. WERFEN HORIBA, Ltd. SEKISUI Diagnostics F. Hoffmann-La Roche Ltd BIOMÉRIEUX QuidelOrtho Corporation Diazyme Laboratories Segment Analysis By Product: The market is led by the reagents & consumables segment in 2023, which held a share of 61.1% owing to its high-volume use for repetitive testing as well as rising demand for standardized product kits available at hospitals and laboratories. Test operation essential: Dynamic filling and dumping, consumables must be recycled frequently. By Test Type: Clinical laboratory tests held the majority share of 59.5% in 2023 on account of higher throughput and the fact that they can process bulk testing effectively, especially in hospitals & diagnostic centers. However, point-of-care tests (POCT) are experiencing the fastest growth owing to their rising application in the emergency department and outpatient care. A major driver is their potential to deliver fast, actionable results at the bedside or in ambulances. By Method: In 2023, the ELISA was responsible for a 39.6% market share driven by its proven efficiency and scalability to clinical lab settings with high accuracy levels. The latex-enhanced immunoturbidimetric assay is a rapidly expanding method with a shorter turnaround time and full integration into automated analyzers, which allows rapid high-throughput testing. By Application: The highest DVT market share was for the deep vein thrombosis (DVT) segment in 2023, with a global spread and significant clinical emphasis on its early detection. Pulmonary embolism (PE) is turning out to be the fastest growing segment, and this growth is particularly attributed to an increase in awareness as well as advancements in detection technologies across emergency medicine. By End-Use: Hospitals controlled the largest share of the market in 2023, at 32.8%. This occurs because of the large number of emergency, ICU, and in-house laboratories capable of carrying out rapid diagnostic work-ups. For a Personalized Briefing with Our Industry Analysts, Connect Now: D-dimer Testing Market Segmentation By Product Analyzers Reagents & Consumables By Test Type Clinical Laboratory Tests Point-of-Care Tests By Method Enzyme-linked Immunosorbent Assay (ELISA) Latex-enhanced Immunoturbidimetric Assays Fluorescence Immunoassays Others By Application Deep Vein Thrombosis (DVT) Pulmonary Embolism (PE) Disseminated Intravascular Coagulation (DIC) Others By End-Use Hospitals Academic & Research Institutes Diagnostic Centers Others Regional Analysis The market in North America is expected to grow at the highest CAGR during the forecast period, driven by high healthcare expenditure, strong laboratory testing base, and a well-developed physician network. The U.S., especially, has high diagnostic rates and cardiovascular disease incidence, thus ruling the region. Asia Pacific is the largest growing region for the anticipated period. The diagnostic field is experiencing an exponential growth in several countries, such as China and India, driven by escalating investments toward healthcare infrastructure development and growing accessibility to POCT products. Several drivers contribute to RT acceptance: heightened public awareness, wider insurance coverage, and government moves against noncommunicable disease. Recent Advances in D-dimer Testing Market Feb 2023 – Carolina Liquid Chemistries Corp. and Diazyme Laboratories added D-dimer to its test menu on the DZ-Lite c270 analyzer, part of a batch of 25 new assays to give diagnosticians more flexibility. April 2024 – Siemens Healthineers introduced an enhanced D-dimer assay to the Atellica Solution platform, which provided enhanced sensitivity and turnaround times for emergency settings. Suggested Unique USP Sections for Client Proposal Prevalence-Based Demand Modeling – Country-wise mapping of thrombotic disease burden vs. current D-dimer testing rates. – Country-wise mapping of thrombotic disease burden vs. current D-dimer testing rates. Point-of-Care Ecosystem Analysis – Mapping adoption trends and infrastructure requirements for POCT expansion across regions. – Mapping adoption trends and infrastructure requirements for POCT expansion across regions. Regulatory & Reimbursement Landscape – Coverage policies, regional regulatory hurdles, and HTA frameworks impacting test adoption. – Coverage policies, regional regulatory hurdles, and HTA frameworks impacting test adoption. AI Integration & Diagnostic Decision Support – Innovations around AI-enhanced interpretation of D-dimer results for clinical triage. – Innovations around AI-enhanced interpretation of D-dimer results for clinical triage. Hospital-Laboratory Partnership Models – Case studies on how labs and hospitals are optimizing diagnostic turnaround and cost via partnerships. – Case studies on how labs and hospitals are optimizing diagnostic turnaround and cost via partnerships. Workflow & Automation Impact Analysis – Efficiency benchmarking of automated platforms vs. manual processing for D-dimer testing. – Efficiency benchmarking of automated platforms vs. manual processing for D-dimer testing. D-dimer in Multi-Analyte Panels – Future scope and pipeline analysis of D-dimer integration into cardiovascular or coagulation biomarker panels. Buy the Full D-dimer Testing Market Report (Single-User License) Now: About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
